You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 9,750,747


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,750,747 protect, and when does it expire?

Patent 9,750,747 protects APTIOM and is included in one NDA.

This patent has five patent family members in four countries.

Summary for Patent: 9,750,747
Title:Treatments involving eslicarbazepine acetate or eslicarbazepine
Abstract: The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in treating or preventing a disorder selected from epilepsy, affective disorders, schizoaffective disorders, bipolar disorders, neuropathic pain and neuropathic pain related disorders, attention disorders, anxiety disorders, sensorimotor disorders, vestibular disorders, and fibromyalgia, in a patient suffering from or susceptible to absence seizures.
Inventor(s): Soares Da Silva; Patricio Manuel Vieira Araujo (Sao Mamede do Coronado, PT)
Assignee: BAIL-PORTELA & CA, S.A. (Sao Mamede do Coronado, PT)
Application Number:14/240,847
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,750,747
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Delivery; Dosage form;

Drugs Protected by US Patent 9,750,747

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sumitomo Pharma Am APTIOM eslicarbazepine acetate TABLET;ORAL 022416-001 Nov 8, 2013 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF PARTIAL-ONSET SEIZURES ⤷  Try a Trial
Sumitomo Pharma Am APTIOM eslicarbazepine acetate TABLET;ORAL 022416-001 Nov 8, 2013 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES ⤷  Try a Trial
Sumitomo Pharma Am APTIOM eslicarbazepine acetate TABLET;ORAL 022416-002 Nov 8, 2013 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES ⤷  Try a Trial
Sumitomo Pharma Am APTIOM eslicarbazepine acetate TABLET;ORAL 022416-002 Nov 8, 2013 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF PARTIAL-ONSET SEIZURES ⤷  Try a Trial
Sumitomo Pharma Am APTIOM eslicarbazepine acetate TABLET;ORAL 022416-003 Nov 8, 2013 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,750,747

PCT Information
PCT FiledAugust 24, 2012PCT Application Number:PCT/PT2012/000031
PCT Publication Date:March 07, 2013PCT Publication Number: WO2013/032351

International Family Members for US Patent 9,750,747

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2847235 ⤷  Try a Trial
European Patent Office 2747770 ⤷  Try a Trial
Russian Federation 2014111478 ⤷  Try a Trial
Russian Federation 2639120 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2013032351 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.